BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...almost clinical. It’s got to be really special for us to do something earlier,” said Lindsay Rosenwald...
...AAV) vector constructs. “It’s got to be really special for us to do something earlier.” Lindsay Rosenwald...
BioCentury | Jan 6, 2014
Company News

Coronado Biosciences management update

...Coronado Biosciences Inc. (NASDAQ:CNDO), Burlington, Mass. Business: Autoimmune, Cancer Transitioned: Lindsay Rosenwald to president, CEO and chairman...
BioCentury | Jan 16, 2012
Finance

IPO end around

...David Strupp of Rodman & Renshaw. Coronado also has Cougar bloodlines: both were co-founded by Lindsay Rosenwald...
...majority of our shareholders are retail," President and CEO Bobby Sandage told BioCentury. "The founder, Lindsay Rosenwald...
BioCentury | Jul 14, 2008
Emerging Company Profile

Corporate Profile

...Calif. Technology: N/A Disease focus: Cancer Clinical status: Phase I Founded: 2007 by Bert Liang, Lindsay Rosenwald...
BioCentury | Nov 13, 2006
Company News

Keryx board of directors update

...Inc. (KERX), New York, N.Y. Business: Renal, Cancer Appointed: Wyche Fowler, former U.S. congressman Resigned: Lindsay Rosenwald WIR...
BioCentury | Sep 8, 2003
Company News

Indevus board of directors update

...Indevus Pharmaceuticals Inc. (IDEV), Lexington, Mass. Business: Urology, Neurology, Infectious Resigned: Alexander Haig Jr.; and Lindsay Rosenwald WIR...
BioCentury | Sep 23, 2002
Finance

Ebb & Flow

...IPO through Thomas Weisel Partners; Wells Fargo; and Jefferies. The company's big backer was financier Lindsay Rosenwald...
BioCentury | Feb 7, 2000
Company News

Interneuron board of directors update

...Layoffs, B6) Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Business: Metabolic, Neurological Resigned: Lindsay Rosenwald as chairman while...
BioCentury | Jul 20, 1998
Finance

British breakaway?

...outstanding after the issuance. An additional 7.3 million shares underlie the converts, warrants and options. Lindsay Rosenwald...
BioCentury | Oct 10, 1994
Finance

Aries Fund seeks to capitalize on bear market

...when it seems that everyone wants to get out of biotech, along come the contrarians. Lindsay Rosenwald...
Items per page:
1 - 10 of 11
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

...almost clinical. It’s got to be really special for us to do something earlier,” said Lindsay Rosenwald...
...AAV) vector constructs. “It’s got to be really special for us to do something earlier.” Lindsay Rosenwald...
BioCentury | Jan 6, 2014
Company News

Coronado Biosciences management update

...Coronado Biosciences Inc. (NASDAQ:CNDO), Burlington, Mass. Business: Autoimmune, Cancer Transitioned: Lindsay Rosenwald to president, CEO and chairman...
BioCentury | Jan 16, 2012
Finance

IPO end around

...David Strupp of Rodman & Renshaw. Coronado also has Cougar bloodlines: both were co-founded by Lindsay Rosenwald...
...majority of our shareholders are retail," President and CEO Bobby Sandage told BioCentury. "The founder, Lindsay Rosenwald...
BioCentury | Jul 14, 2008
Emerging Company Profile

Corporate Profile

...Calif. Technology: N/A Disease focus: Cancer Clinical status: Phase I Founded: 2007 by Bert Liang, Lindsay Rosenwald...
BioCentury | Nov 13, 2006
Company News

Keryx board of directors update

...Inc. (KERX), New York, N.Y. Business: Renal, Cancer Appointed: Wyche Fowler, former U.S. congressman Resigned: Lindsay Rosenwald WIR...
BioCentury | Sep 8, 2003
Company News

Indevus board of directors update

...Indevus Pharmaceuticals Inc. (IDEV), Lexington, Mass. Business: Urology, Neurology, Infectious Resigned: Alexander Haig Jr.; and Lindsay Rosenwald WIR...
BioCentury | Sep 23, 2002
Finance

Ebb & Flow

...IPO through Thomas Weisel Partners; Wells Fargo; and Jefferies. The company's big backer was financier Lindsay Rosenwald...
BioCentury | Feb 7, 2000
Company News

Interneuron board of directors update

...Layoffs, B6) Interneuron Pharmaceuticals Inc. (IPIC), Lexington, Mass. Business: Metabolic, Neurological Resigned: Lindsay Rosenwald as chairman while...
BioCentury | Jul 20, 1998
Finance

British breakaway?

...outstanding after the issuance. An additional 7.3 million shares underlie the converts, warrants and options. Lindsay Rosenwald...
BioCentury | Oct 10, 1994
Finance

Aries Fund seeks to capitalize on bear market

...when it seems that everyone wants to get out of biotech, along come the contrarians. Lindsay Rosenwald...
Items per page:
1 - 10 of 11